Frontlight ResearchEarly access
Not yet recruitingPhase 1
Safety of AGMB-101 in healthy people and people with liver cirrhosis
Tests how safe AGMB-101 is in healthy volunteers and people with liver cirrhosis.
Key facts
- Who runs it
- AgomAb Therapeutics
- Where
- Belgium1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- A study to evaluate the safety and tolerability of single ascending doses of AGMB-101 in healthy participants (Part A) and patients with liver cirrhosis (Part B).
- Status
- Not yet recruiting
- Phase
- Phase 1
- People taking part
- 64 people, planned
- Started
- 3 Mar 2025
- Planned end
- 7 Jan 2026
- Type of study
- Interventional
- Record updated
- 27 February 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for healthy adults (Part A) and adults with liver cirrhosis, which is scarring of the liver (Part B). It tests single, rising doses of AGMB-101.
- Age
- 18 years and older
- Sex
- All sexes
- Disease stage
- Part B: people with liver cirrhosis. Part A: healthy people.
Where is this trial?
It has sites in one country. Choose a country to see its sites.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Plain-language title
- Safety of AGMB-101 in healthy people and people with liver cirrhosisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 27 February 2025